HSP90AB2P

Putative heat shock protein HSP 90-beta 2 · Q58FF8 · HSP90AB2P on Sugi Atlas →

440 patent compounds predicted against HSP90AB2P, 307 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Crenolanib (SCHEMBL2730601)	1.00	1/20
Crenolanib (SCHEMBL29350134)	1.00	1/20
Crenolanib (SCHEMBL29352568)	1.00	1/20
Crenolanib (SCHEMBL30002138)	1.00	1/20
SCHEMBL22567082	0.86	1/20
SCHEMBL5662568	0.85	1/20
Crenolanib (SCHEMBL4681285)	0.85	1/20
Crenolanib (SCHEMBL29352554)	0.85	1/20
Crenolanib (SCHEMBL29361948)	0.85	1/20
SCHEMBL27030604	0.85	1/20
SCHEMBL30775111	0.85	1/20
SCHEMBL23026363	0.82	1/20
SCHEMBL3191766	0.80	1/20
SCHEMBL27030775	0.80	1/20
SCHEMBL30441378	0.80	1/20
SCHEMBL3180117	0.79	1/20
SCHEMBL3189249	0.78	1/20
SCHEMBL3190082	0.78	1/20
SCHEMBL3190135	0.78	1/20
SCHEMBL3182258	0.76	1/20

Clinical trials — most relevant to HSP90AB2P by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma	PHASE3	COMPLETED
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease	PHASE2	COMPLETED
OGX-427 in Castration Resistant Prostate Cancer Patients	PHASE2	COMPLETED
A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer	PHASE2	COMPLETED
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC)	PHASE1/PHASE2	COMPLETED
LBH589 Plus Decitabine for Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)	PHASE1/PHASE2	COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas	PHASE1	COMPLETED
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma	PHASE1	COMPLETED
Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma	PHASE1	COMPLETED
HS-201, an HSP90 Inhibitor-linked Verteporfin for Detection of Solid Malignancies	PHASE1	WITHDRAWN
Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Study of IPI-504 and Docetaxel in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors	PHASE1	COMPLETED
LncRNA Nicotinamide Nucleotide Transhydrogenase-Antisense RNA1 NNT-AS1 in CRC	nan	COMPLETED
The Role of HSP90 in Peripheral Vascular Lesions of Diabetic Atherosclerosis	nan	COMPLETED
Perfusion-Induced Hyperthermia for Metastatic Carcinoma	nan	COMPLETED
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk	nan	COMPLETED
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)	nan	RECRUITING
BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer	nan	UNKNOWN
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases.	nan	NOT_YET_RECRUITING
Acute Passive Heating in Healthy Older Adults	nan	COMPLETED
Chronic Heat Therapy for Improving Vascular Health	nan	COMPLETED
Trial of Nonsurgical Treatment of Intermittent Claudication Due to Femoro-popliteal Disease	nan	COMPLETED
Cardioprotective Benefit of Passive Heat Therapy in Higher-Level Spinal Cord Injury: Safety and Proof of Concept	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a HSP90AB2P binder may also engage these)

Protein	Name	Similarity
Q58FG1	—	0.994	Q58FG1 →
P0DQH9	—	0.993	P0DQH9 →
BCCIP	BRCA2 and CDKN1A-interacting protein	0.992	landscape →
P0DJS9	—	0.992	P0DJS9 →
A2C4X2	—	0.992	A2C4X2 →
Q7MWL6	—	0.992	Q7MWL6 →
Q3Z2X0	—	0.992	Q3Z2X0 →
Q4PLZ3	—	0.992	Q4PLZ3 →
Q2U600	—	0.992	Q2U600 →
Q6NYD4	—	0.991	Q6NYD4 →
P0DJS8	—	0.991	P0DJS8 →
P0CK83	—	0.991	P0CK83 →
P02890	—	0.991	P02890 →
A4J0B0	—	0.991	A4J0B0 →
P0DJR6	—	0.991	P0DJR6 →
Q74LB6	—	0.990	Q74LB6 →
Q57778	—	0.990	Q57778 →
P06747	—	0.990	P06747 →
P0DJW1	—	0.990	P0DJW1 →
P0DJR7	—	0.990	P0DJR7 →
P0DJV4	—	0.990	P0DJV4 →
P29999	—	0.990	P29999 →
P0DJT1	—	0.990	P0DJT1 →
P0CK78	—	0.990	P0CK78 →
B2RIG0	—	0.990	B2RIG0 →
P0DJT0	—	0.990	P0DJT0 →
DTD1	D-aminoacyl-tRNA deacylase 1	0.990	landscape →
P0DJS3	—	0.990	P0DJS3 →
P0DJS0	—	0.990	P0DJS0 →
P0DJR9	—	0.989	P0DJR9 →